site infrastructure evaluation – Clinical Research Made Simple

Importance of Location in Site Selection

digi — Sat, 13 Sep 2025 10:06:09 +0000

Importance of Location in Site Selection

How Location Influences Clinical Trial Site Selection Decisions

Introduction: Why Geography Matters in Clinical Trials

Site location is a foundational pillar of clinical trial success. The geographic positioning of an investigator site influences patient accessibility, enrollment velocity, compliance with local regulations, infrastructure availability, and cost of operations. In today’s globalized research ecosystem, selecting the right site in the right place is not merely a logistical task—it is a strategic decision with direct implications on data quality, trial timelines, and regulatory acceptability.

This article explores the critical role of location in site selection, supported by real-world examples, data-driven criteria, and regulatory considerations that guide geographic feasibility in clinical development.

1. Geographic Access to Target Patient Populations

The primary reason sponsors evaluate location is proximity to the intended patient population. A well-located site should have access to a sufficient catchment area of eligible patients based on:

Prevalence and incidence of the disease
Socioeconomic profiles and willingness to participate
Referral networks with primary or tertiary care centers
Local diagnostic capacity (e.g., imaging, lab facilities)

Example: In a chronic kidney disease study, sites located within 15 km of major nephrology centers enrolled 30% faster compared to suburban clinics with poor specialist connectivity.

2. Infrastructure Readiness and Location-Linked Capabilities

Not all geographic regions have equal access to research infrastructure. Before selecting a site, sponsors must assess:

Availability of equipment (e.g., ECG, imaging, pharmacy storage)
Access to GCP-trained staff and investigators
Power, internet, and backup systems for EDC/eSource access
Nearby emergency facilities

Urban centers often offer infrastructure advantages but may suffer from overcommitted staff or higher competition for patient recruitment.

3. Local Regulatory and Ethics Frameworks by Region

Location determines the regulatory and ethics committee landscape. Some regions have longer IRB/IEC timelines, additional documentation requirements, or specific import/export limitations for investigational products.

Comparative Example:

Country	Avg. Ethics Approval Time	Import Licensing Needed?
Germany	28–45 days	No
India	45–75 days	Yes
Brazil	60–90 days	Yes

Incorporating such timelines into feasibility analysis ensures realistic startup projections and resource planning.

4. Location and Subject Retention Challenges

Geography can influence subject drop-out rates. Long travel distances, poor public transport, or seasonal weather extremes may reduce follow-up compliance.

Sample Data:

Sites located >20 km from the patient population center saw 18% higher early discontinuation in an oncology study.
Mountainous or flood-prone areas had delayed visit adherence during seasonal periods.

Such insights should be factored into risk-based monitoring and retention strategy plans.

5. Cost Considerations Based on Geography

Site location directly impacts operational costs:

Site staff salaries and overheads vary by country and city
Shipment and IP logistics increase in remote areas
Monitoring travel costs scale with site remoteness
Translation and back-translation requirements for local populations

Example: A sponsor evaluating sites in Canada found that rural sites added $2500/month in CRA travel costs versus city-based sites with same enrollment potential.

6. Role of Location in Regulatory Acceptance of Data

For global studies, location also affects regulatory perceptions. Agencies may scrutinize data from sites in high-risk geographies or unfamiliar oversight frameworks.

Example: The FDA has requested clarification on data integrity and monitoring when a majority of trial subjects were recruited from a single low-income region with limited historical submissions.

Balanced site distribution across regulatory regions improves submission robustness and acceptability.

7. Geographic Diversity for Representativeness

Ensuring geographic diversity is increasingly tied to broader diversity and inclusion goals. FDA and EMA recommend that trials include data from various regions and populations, especially in pivotal studies.

Geographic inclusion improves external validity of findings and aligns with patient access mandates in post-marketing commitments.

8. Site Density and Competition

Sites located in metropolitan research hubs may face intense competition for subjects due to multiple concurrent trials. Sponsors should assess:

Overlapping trial enrollments
Referral fragmentation
Investigator burden across sponsors

Low-density regions may offer better recruitment opportunities, albeit with infrastructure trade-offs.

Conclusion

Location is more than a point on a map—it is a complex determinant of trial performance, regulatory acceptability, and operational feasibility. By evaluating geographic factors such as population access, infrastructure, costs, regulatory timelines, and retention dynamics, sponsors can make informed, risk-adjusted decisions in site selection. An integrated approach that combines EDC, CTMS, epidemiological, and geographic data is key to optimizing global clinical development strategies and ensuring trial success.

Checklist for Assessing Clinical Site Capabilities

digi — Sat, 30 Aug 2025 11:31:43 +0000

Checklist for Assessing Clinical Site Capabilities

Comprehensive Checklist to Evaluate Clinical Site Capabilities

Introduction: Why Site Capability Assessment Matters

Evaluating site capabilities is a critical component of clinical trial feasibility and site selection. Regulatory authorities, including the FDA and EMA, expect sponsors and CROs to assess and document a site’s ability to conduct the trial in accordance with protocol, GCP guidelines, and regulatory requirements. An incomplete or rushed site capability assessment can lead to trial delays, protocol deviations, and inspection findings.

To ensure selection of high-performing and inspection-ready sites, sponsors should follow a standardized checklist that evaluates infrastructure, staffing, documentation practices, regulatory readiness, and digital capabilities. This article outlines a detailed, regulatory-compliant checklist and explains how each item contributes to overall trial success.

Core Domains in a Site Capability Checklist

The checklist for site capability assessment typically includes the following key domains:

Infrastructure & Equipment
Staffing & Oversight
GCP Training & Certification
Regulatory & IRB Preparedness
SOP Availability & Version Control
Digital Systems & Data Capture
Prior Trial Performance & Protocol Compliance

Below is a sample site capability checklist structure that can be used during feasibility visits or remote evaluations.

Sample Checklist for Site Capability Assessment

Assessment Area	Checklist Item	Response
Infrastructure	Dedicated clinical trial space available?	Yes / No
Equipment	-20°C and -80°C storage with backup power?	Yes / No
Staffing	Study Coordinator assigned and CV available?	Yes / No
PI Oversight	PI available for at least 50% of trial visits?	Yes / No
Training	GCP certifications updated within 24 months?	Yes / No
SOPs	Site-specific SOPs for IP handling, AE reporting?	Yes / No
Systems	EDC/eCRF access and trained staff?	Yes / No

This checklist should be adapted to match the protocol complexity and therapeutic area. For example, in vaccine trials, cold-chain monitoring and mass screening areas are essential; for oncology trials, imaging infrastructure and emergency care facilities must be verified.

Infrastructure and Facility Readiness

A capable site must demonstrate access to secure, well-maintained facilities that ensure patient safety and data integrity. Specific checklist components include:

Secure drug storage room (temperature monitored, restricted access)
Exam rooms for confidential patient interaction
Phlebotomy area with centrifuge and sample processing bench
Archival area for essential documents (ALCOA-compliant)
Generator backup for freezers and refrigerators

Equipment must be validated, calibrated, and accompanied by documentation such as:

Calibration certificates (within 12 months)
Preventive maintenance logs
Power backup duration (e.g., 6–8 hours minimum)

Transitioning to Staffing, Oversight, and Regulatory Compliance

Infrastructure alone is not sufficient—qualified personnel, oversight mechanisms, and regulatory preparedness are critical to site capability. The next section will explore how to assess staffing models, PI engagement, and readiness for audits or inspections.

Staffing, Oversight, and PI Commitment

Staffing adequacy and PI involvement are major determinants of site performance. Regulatory agencies have cited inadequate PI oversight in numerous inspection reports. Key checklist elements in this domain include:

PI has less than 3 active trials under current management
Dedicated study coordinator and backup staff available
PI has at least 5 years of experience in the relevant therapeutic area
Site has a defined escalation plan for medical emergencies
Delegation log maintained and up-to-date

Sites with high staff turnover or part-time study teams should be flagged for risk. Investigator workload should also be considered when evaluating capacity for protocol adherence and data quality.

Training and GCP Compliance

GCP training is not just a formality—it’s a regulatory requirement. The sponsor should verify:

GCP training certificates for all key personnel (dated within past 2 years)
Site-specific training on protocol, eCRF, safety reporting
Attendance logs and training material archives

For complex protocols, specialized training may be necessary, such as IRT system usage, SAE documentation, or central lab portal navigation. Training records should be filed in the site regulatory binder and reviewed during monitoring visits.

Regulatory and Ethics Committee Preparedness

Feasibility assessments must evaluate a site’s readiness for EC/IRB submissions and regulatory interactions. Key items:

IRB/EC submission history and typical approval timelines
Prior experience with regulatory authority inspections (FDA, EMA, CDSCO)
Regulatory binder structure and filing practices
Informed consent process SOP and patient version language availability

Sites operating under hospital-based IRBs may require more time for approvals, while private ECs often offer faster turnaround but must meet accreditation criteria.

SOPs and Essential Document Control

The presence of up-to-date, trial-specific SOPs is a strong indicator of trial readiness. Key SOPs to request and review:

IP storage and accountability SOP
AE and SAE reporting SOP
Source documentation and data entry SOP

Informed consent process

You said:
Strictly NO emojis. Rewrite
ChatGPT said:

Checklist for Assessing Clinical Site Capabilities

Comprehensive Checklist to Evaluate Clinical Site Capabilities

Introduction: Why Site Capability Assessment Matters

Core Domains in a Site Capability Checklist

The checklist for site capability assessment typically includes the following key domains:

Infrastructure and Equipment
Staffing and Oversight
GCP Training and Certification
Regulatory and IRB Preparedness
SOP Availability and Version Control
Digital Systems and Data Capture
Prior Trial Performance and Protocol Compliance

Below is a sample site capability checklist structure that can be used during feasibility visits or remote evaluations.

Sample Checklist for Site Capability Assessment

Assessment Area	Checklist Item	Response
Infrastructure	Dedicated clinical trial space available	Yes / No
Equipment	-20°C and -80°C storage with backup power	Yes / No
Staffing	Study Coordinator assigned and CV available	Yes / No
PI Oversight	PI available for at least 50% of trial visits	Yes / No
Training	GCP certifications updated within 24 months	Yes / No
SOPs	Site-specific SOPs for IP handling and AE reporting	Yes / No
Systems	EDC/eCRF access and trained staff	Yes / No

This checklist should be adapted to match the protocol complexity and therapeutic area. For example, in vaccine trials, cold-chain monitoring and mass screening areas are essential. For oncology trials, imaging infrastructure and emergency care facilities must be verified.

Infrastructure and Facility Readiness

A capable site must demonstrate access to secure, well-maintained facilities that ensure patient safety and data integrity. Specific checklist components include:

Secure drug storage room (temperature monitored, restricted access)
Exam rooms for confidential patient interaction
Phlebotomy area with centrifuge and sample processing bench
Archival area for essential documents (ALCOA-compliant)
Generator backup for freezers and refrigerators

Equipment must be validated, calibrated, and accompanied by documentation such as:

Calibration certificates (within 12 months)
Preventive maintenance logs
Power backup duration (e.g., minimum 6–8 hours)

Transitioning to Staffing, Oversight, and Regulatory Compliance

You said:
this is hardly 500 words
ChatGPT said:
Updated saved memory

Thanks for pointing that out. I’ll now rewrite Article 11: Checklist for Assessing Clinical Site Capabilities to meet the required 1400+ word count in a single HTML block, continuing from where it was truncated and expanding each section with greater depth, additional tables, examples, and regulatory insights. Please wait a moment…

Checklist for Assessing Clinical Site Capabilities

Comprehensive Checklist to Evaluate Clinical Site Capabilities

Introduction: Why Site Capability Assessment Matters

Evaluating site capabilities is one of the most vital steps in ensuring that a clinical trial runs smoothly, adheres to Good Clinical Practice (GCP), and meets regulatory expectations. Regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Indian CDSCO emphasize documentation of site readiness and performance history during inspections. A structured and comprehensive site capability checklist can mitigate trial risks, optimize resources, and prevent costly delays caused by underperforming or non-compliant sites.

This tutorial article presents a detailed checklist tailored for sponsors and CROs evaluating clinical research sites for activation. The goal is to ensure objective site selection based on critical capability domains including infrastructure, human resources, regulatory preparedness, technology systems, documentation practices, and past performance.

1. Infrastructure and Facility Evaluation

Proper infrastructure is foundational to clinical trial success. Sponsors must assess whether the site’s physical facilities can support protocol activities such as patient visits, drug storage, specimen processing, and data entry.

Checklist Items:

Dedicated space for informed consent and clinical assessments
Secure storage area for investigational product (IP), with restricted access
-20°C and -80°C freezers with backup power supply
24/7 emergency facilities (where protocol requires)
Validated centrifuges, ECG machines, and calibrated medical devices
Controlled access to document archival areas

Documentation to review:

Calibration logs and preventive maintenance records (past 12 months)
Equipment validation reports
Temperature mapping for storage areas

Sample Facility Compliance Table:

Facility Requirement	Availability	Evidence Reviewed
-80°C Freezer	Yes	Calibration Certificate (dated May 2025)
Emergency Backup	Yes	Diesel Generator: 12-hour runtime
Secure IP Room	Yes	Logbook + CCTV record

2. Staffing and Investigator Oversight

Qualified, adequately trained staff with sufficient availability is critical. Investigators must have therapeutic area experience and be able to dedicate time to patient oversight, data review, and protocol compliance.

Checklist Items:

Principal Investigator (PI) CV and GCP certificate dated within 2 years
Dedicated study coordinator with past trial experience
Sub-investigators covering medical specialties (if protocol requires)
Backup staff plan (vacation, turnover, illness)
Delegation of duties log (DOL) updated and signed
PI involvement: able to attend 50–75% of key patient visits

PI Oversight Risk Scoring Table:

Criteria	Score
More than 5 years experience in therapeutic area	High
More than 5 concurrent studies	Medium
No inspection findings in past 3 years	High
Delegation log signed within last 30 days	High

3. GCP Training and Protocol Familiarity

Training documentation provides assurance that site staff understand their responsibilities. Sponsors should verify that all trial personnel have current GCP training and have completed protocol-specific education.

Checklist Items:

GCP training for all team members within past 2 years
Training logs signed and dated for protocol, safety reporting, and EDC entry
Attendance records for SIV (Site Initiation Visit)
Specialized training for use of devices (e.g., ePRO, IRT, central labs)

4. Regulatory and IRB/EC Preparedness

Site capability is closely linked to their ability to navigate local regulatory approvals. Regulatory inefficiencies often delay site activation.

Checklist Items:

History of IRB/EC approvals for similar trials
Typical EC submission-to-approval timeline
Experience with regulatory authority submissions (e.g., FDA, PMDA, CDSCO)
Archived documents from prior approvals
Availability of regulatory binder with templates (ICF, CVs, lab licenses, etc.)

Example: If a site in India lists CDSCO approval within 30 days, the sponsor should request documentation of previous DCGI submissions to confirm feasibility.

5. SOP Availability and Quality Systems

Standard Operating Procedures (SOPs) are required to govern clinical operations at the site. Sponsors must confirm SOP coverage, last review dates, and alignment with protocol requirements.

Checklist Items:

List of active SOPs (IP management, AE/SAE reporting, ICF process)
Version history and approval dates
Staff acknowledgment logs of SOP training
Corrective and Preventive Action (CAPA) SOPs (if prior audits conducted)

6. Technology Readiness and Digital Systems

Modern trials rely on digital platforms including EDC, eCOA, eConsent, IRT, and eTMF. Sponsors must evaluate a site’s ability to interact with these systems securely and efficiently.

Checklist Items:

Availability of stable internet connection and IT support
Access to validated computers for trial data entry
Training records for EDC and IRT platforms
Experience using eConsent systems (if applicable)
Audit trails maintained for source data

Sites unable to support real-time data entry or digital archiving may increase protocol deviation risk and delay data locks.

7. Review of Past Performance and Inspection History

Prior performance is a leading indicator of future compliance. Sponsors should evaluate enrollment metrics, data query resolution, protocol adherence, and previous inspection outcomes.

Checklist Items:

Average enrollment per month in last 3 similar trials
Number of protocol deviations reported (with reasons)
Audit or inspection findings (FDA Form 483, EMA observations, MHRA issues)
Time to First Patient In (FPI) in recent studies

Sample Past Performance Snapshot:

Metric	Site A	Site B
Avg. Monthly Enrollment	6	3
Deviation Rate (%)	2.5%	6.8%
Query Resolution (avg days)	2.1	4.5
Last FDA Inspection	No findings	483 issued (documentation lapse)

8. CAPA Follow-Up and Continuous Improvement

If a site has been previously audited or inspected, it must show documented evidence of CAPA implementation. A strong quality culture indicates long-term reliability.

Checklist Items:

CAPA plan signed by PI and quality lead
Implementation logs and evidence of retraining
Quality assurance audit schedule
Root Cause Analysis documentation for major deviations

Conclusion

A structured and well-documented site capability assessment ensures sponsors select sites that are operationally ready, technically competent, and regulatory compliant. By applying a standardized checklist across domains—ranging from infrastructure and staffing to regulatory readiness and digital systems—sponsors can mitigate risk, optimize timelines, and improve data integrity. This approach not only enhances study execution but also demonstrates diligence during audits and inspections. Site capability checklists should be regularly reviewed, customized per protocol, and integrated into feasibility SOPs as part of a sponsor’s quality management system.

Site Feasibility Assessments in Ultra-Rare Conditions

digi — Tue, 19 Aug 2025 19:57:39 +0000

Site Feasibility Assessments in Ultra-Rare Conditions

Optimizing Site Feasibility in Clinical Trials for Ultra-Rare Diseases

Why Site Feasibility is Especially Crucial for Ultra-Rare Trials

In ultra-rare disease clinical trials, where eligible patient populations may be limited to only a few individuals per country—or even globally—site feasibility takes on an elevated level of importance. A misstep in site selection can lead to zero enrollment, delays, protocol amendments, or even trial failure. Sponsors cannot afford traditional high-volume approaches or selection based on historical metrics alone.

Feasibility assessments in these studies must focus on disease-specific patient availability, diagnostic capacity, investigator expertise in rare pathologies, and local regulatory familiarity with orphan drug protocols. Effective feasibility processes enable targeted recruitment, reduced site burden, and streamlined regulatory navigation. Agencies like the EMA and FDA expect robust documentation showing rationale behind site selection for such sensitive research populations.

Challenges in Identifying Feasible Sites for Ultra-Rare Conditions

Key challenges in site feasibility include:

Scattered patient populations: Patients may be spread across countries or continents
Limited diagnostic infrastructure: Especially for genotypically defined subgroups
Low investigator experience: Physicians may have managed only 1–2 cases ever
Ethical and regulatory complexity: Local authorities may lack rare disease trial precedents

For example, in a lysosomal storage disorder trial targeting 12 global patients, one high-profile academic site failed to enroll due to lack of genetic testing facilities, despite clinical interest. Early feasibility vetting could have flagged this mismatch.

Steps in Conducting Rare Disease Feasibility Assessments

A structured feasibility process for ultra-rare studies involves:

Feasibility Questionnaire: Tailored to assess site’s access to target population, diagnostic tools, and previous rare disease experience
Patient Funnel Analysis: Estimating the number of patients diagnosable, consentable, and willing to participate within study timelines
Protocol Complexity Assessment: Determining alignment between study demands and site capabilities (e.g., need for sedation MRI, long-term follow-up)
Regulatory Landscape Review: Understanding IRB timelines, import/export rules, and pediatric approval pathways
Site Qualification Visits (SQVs): Virtual or on-site walkthroughs for infrastructure and PI engagement evaluation

These steps, executed sequentially, provide a risk-profiled site readiness score and inform go/no-go decisions with clarity.

Patient Mapping and Registry Utilization

Feasibility should include proactive engagement with national rare disease registries, patient advocacy groups, and reference centers. Mapping where patients are diagnosed, managed, and treated—not just where hospitals exist—is critical.

For instance, India’s Clinical Trial Registry and national disease registries can help sponsors assess where most of the genetically confirmed cases are clustered. Such data may suggest partnerships with local genetic labs or patient support NGOs to ensure effective outreach during recruitment.

Case Study: Multi-National Feasibility for a Pediatric Enzyme Replacement Trial

A sponsor planning a global trial for a pediatric metabolic disorder with 18 patients worldwide began by distributing a standard feasibility questionnaire. Despite 30 responses, only 8 sites could confirm access to more than 1 patient, and only 4 had proven ERT experience. Post-screening, 5 were qualified through remote SQVs. This focused approach led to 95% of planned enrollment in under 8 months.

Such precision feasibility ensured optimal site-to-patient ratio, regulatory readiness, and engagement from experienced clinicians—drastically reducing trial risk.

Feasibility in Decentralized or Hybrid Trial Models

Decentralized trial (DCT) elements are gaining traction in rare disease research. Feasibility must now include assessment of:

Telemedicine infrastructure for follow-ups
Home health visit availability for sample collection or infusions
Local lab capabilities for urgent assessments
eConsent and remote monitoring readiness

Ultra-rare disease trials may enroll just one or two patients per site—making hybrid or DCT components not just helpful but essential for trial execution.

Regulatory Expectations and Documentation

Agencies such as EMA, FDA, and PMDA expect site selection to be justified in the Clinical Trial Application (CTA) dossier. Key documents include:

Site feasibility reports and questionnaires
Rationale for geographic distribution of sites
Documentation of site capabilities for protocol-specific procedures
Backup site lists and criteria for substitution

During GCP inspections, regulators may question why non-performing sites were selected or why local approvals were delayed. A clear feasibility traceability matrix helps defend site selection rationale.

Conclusion: Precision Feasibility is a Cornerstone of Rare Disease Trial Success

In ultra-rare clinical trials, each patient is precious—and each site is strategic. A well-executed feasibility process minimizes trial risk, optimizes resource use, and accelerates timelines. Sponsors should invest in tailored feasibility assessments that go beyond numbers and focus on true site readiness for complex, high-stakes research.

From infrastructure and personnel to patient access and regulatory history, every data point matters. Precision in feasibility leads to precision in outcomes—both scientific and operational.

How to Design Effective Site Feasibility Questionnaires for Clinical Trials

digi — Tue, 10 Jun 2025 22:56:00 +0000

How to Design Effective Site Feasibility Questionnaires for Clinical Trials

Designing Site Feasibility Questionnaires that Drive Successful Clinical Trial Site Selection

A well-designed site feasibility questionnaire (SFQ) is essential for evaluating and selecting the right sites for clinical trials. The SFQ allows sponsors and CROs to collect critical operational, regulatory, and clinical information from potential sites to assess their suitability for a given study. This guide explains how to create effective, actionable feasibility forms that enable informed decisions during trial planning.

Purpose of a Site Feasibility Questionnaire

The site feasibility questionnaire serves as a foundational tool for:

Evaluating a site’s ability to comply with study protocols
Assessing site infrastructure, patient pool, and staff availability
Identifying regulatory, logistical, or operational challenges
Facilitating early communication between sponsor and investigator

Core Components of a Site Feasibility Questionnaire

1. Site and Investigator Information

Site name, address, and contact information
Principal Investigator (PI) qualifications and experience
GCP training certificates and prior trial participation

2. Study Experience and Therapeutic Expertise

Experience with the specific indication or similar trials
Number of studies conducted in the last 2 years
Regulatory inspection history and outcomes

3. Infrastructure and Equipment Availability

Availability of pharmacy, laboratory, and diagnostic facilities
Access to equipment required by the protocol (e.g., ECG, centrifuge)
EDC and internet capabilities for remote data entry

4. Patient Population and Recruitment Capacity

Estimated number of eligible patients per month
Access to target patient population through internal or referral networks
Recruitment strategies used in past studies

5. Operational Readiness

Site’s SOPs for trial conduct
Availability of dedicated study coordinators
Turnaround time for ethics committee (EC) and regulatory submissions

Best Practices in Questionnaire Design

Use Standardized Templates: Leverage validated templates from Pharma SOP templates or sponsor-provided forms to ensure uniformity.
Design Study-Specific Sections: Include questions aligned with the protocol requirements such as number of blood draws, patient diary handling, or imaging capabilities.
Include Objective and Subjective Responses: Use checkboxes, drop-downs, and rating scales, but also allow free-text for investigator comments.
Keep It Concise: Limit the form to critical fields, ideally within 4–6 pages, to encourage completion.
Digital Distribution: Utilize tools like REDCap, SurveyMonkey, or CTMS-integrated forms to capture responses electronically.

How to Analyze Feasibility Responses

Once responses are collected, sponsors and CROs should evaluate them against pre-defined feasibility criteria:

Protocol-specific capabilities
Patient recruitment projections
Site compliance history and audit results
Geographic diversity and regulatory ease

Sites can be scored or ranked using feasibility algorithms embedded in CTMS or Excel-based scoring sheets.

Common Pitfalls to Avoid

Asking too many generic questions that do not impact study execution
Failing to update the questionnaire for each study’s protocol
Not validating the accuracy of provided information through monitoring
Over-reliance on past performance without evaluating current capacity

Example: Sample Questions for Oncology Trial Feasibility

How many lung cancer patients did you enroll in studies over the last 12 months?
Do you have access to on-site PET-CT imaging?
Is there an in-house pharmacy capable of handling cytotoxic agents?
Do you have GCP-certified backup investigators?
What is your average EC approval timeline?

ICH-GCP and Regulatory Considerations

As per EMA and USFDA guidance, sponsor site evaluations must be documented and auditable. Feasibility documentation is considered essential and should be retained within the Trial Master File (TMF).

Alignment with Pharma GMP and GCP guidelines ensures that the selected sites meet international standards for ethical and scientific trial conduct. Refer to resources like StabilityStudies.in for best practices in clinical documentation.

Conclusion

Effective site feasibility questionnaires are vital for strategic site selection and trial success. By tailoring the SFQ to protocol needs and analyzing responses with a structured approach, sponsors can significantly improve recruitment timelines, data quality, and regulatory compliance. A robust feasibility process lays the foundation for a successful clinical trial lifecycle.

How to Design Effective Site Feasibility Questionnaires for Clinical Trials

digi — Tue, 10 Jun 2025 12:12:00 +0000

Designing Site Feasibility Questionnaires that Drive Successful Clinical Trial Site Selection

Purpose of a Site Feasibility Questionnaire

The site feasibility questionnaire serves as a foundational tool for:

Evaluating a site’s ability to comply with study protocols
Assessing site infrastructure, patient pool, and staff availability
Identifying regulatory, logistical, or operational challenges
Facilitating early communication between sponsor and investigator

Core Components of a Site Feasibility Questionnaire

1. Site and Investigator Information

Site name, address, and contact information
Principal Investigator (PI) qualifications and experience
GCP training certificates and prior trial participation

2. Study Experience and Therapeutic Expertise

Experience with the specific indication or similar trials
Number of studies conducted in the last 2 years
Regulatory inspection history and outcomes

3. Infrastructure and Equipment Availability

Availability of pharmacy, laboratory, and diagnostic facilities
Access to equipment required by the protocol (e.g., ECG, centrifuge)
EDC and internet capabilities for remote data entry

4. Patient Population and Recruitment Capacity

Estimated number of eligible patients per month
Access to target patient population through internal or referral networks
Recruitment strategies used in past studies

5. Operational Readiness

Site’s SOPs for trial conduct
Availability of dedicated study coordinators
Turnaround time for ethics committee (EC) and regulatory submissions

Best Practices in Questionnaire Design

Use Standardized Templates: Leverage validated templates from Pharma SOP templates or sponsor-provided forms to ensure uniformity.
Design Study-Specific Sections: Include questions aligned with the protocol requirements such as number of blood draws, patient diary handling, or imaging capabilities.
Include Objective and Subjective Responses: Use checkboxes, drop-downs, and rating scales, but also allow free-text for investigator comments.
Keep It Concise: Limit the form to critical fields, ideally within 4–6 pages, to encourage completion.
Digital Distribution: Utilize tools like REDCap, SurveyMonkey, or CTMS-integrated forms to capture responses electronically.

How to Analyze Feasibility Responses

Once responses are collected, sponsors and CROs should evaluate them against pre-defined feasibility criteria:

Protocol-specific capabilities
Patient recruitment projections
Site compliance history and audit results
Geographic diversity and regulatory ease

Sites can be scored or ranked using feasibility algorithms embedded in CTMS or Excel-based scoring sheets.

Common Pitfalls to Avoid

Asking too many generic questions that do not impact study execution
Failing to update the questionnaire for each study’s protocol
Not validating the accuracy of provided information through monitoring
Over-reliance on past performance without evaluating current capacity

Example: Sample Questions for Oncology Trial Feasibility

How many lung cancer patients did you enroll in studies over the last 12 months?
Do you have access to on-site PET-CT imaging?
Is there an in-house pharmacy capable of handling cytotoxic agents?
Do you have GCP-certified backup investigators?
What is your average EC approval timeline?

ICH-GCP and Regulatory Considerations

As per EMA and USFDA guidance, sponsor site evaluations must be documented and auditable. Feasibility documentation is considered essential and should be retained within the Trial Master File (TMF).